Sanofi (SNY) Goodwill & Intangibles (2009 - 2026)
Sanofi (SNY) posted Goodwill & Intangibles of $79.4 billion for Q2 2026, down 1.83% sequentially from $80.9 billion in Q1 2026, and up 15.54% YoY from $68.7 billion in Q2 2025.
Sanofi (SNY) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Sanofi has reported Goodwill & Intangibles for 18 years, with the latest figure at $79.4 billion in Q2 2026.
- Quarterly Goodwill & Intangibles rose 15.54% year-over-year to $79.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $79.4 billion (up 15.54% YoY) and the FY2025 annual result came in at $78.6 billion, up 11.49% from the prior year.
- Goodwill & Intangibles retreated to $79.4 billion in Q2 2026 per SNY's latest filing, from $80.9 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $82.6 billion in Q2 2024 and troughed at $67.1 billion in Q1 2025.
- A 5-year average of $76.5 billion and a median of $79.0 billion in 2025 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2025 and 2026: Goodwill & Intangibles retreated 16.83% in 2025, then rose 20.5% in 2026.
- Over 5 years, Goodwill & Intangibles stood at $73.0 billion in 2022, then grew by 8.69% to $79.3 billion in 2023, then fell by 11.07% to $70.5 billion in 2024, then increased by 11.49% to $78.6 billion in 2025, then rose by 0.97% to $79.4 billion in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $79.4 billion, $80.9 billion, and $78.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.40 Bn |
| Mar 31, 2026 | 80.88 Bn |
| Dec 31, 2025 | 78.64 Bn |
| Sep 30, 2025 | 80.51 Bn |
| Jun 30, 2025 | 68.73 Bn |
| Mar 31, 2025 | 67.12 Bn |
| Dec 31, 2024 | 70.54 Bn |
| Jun 30, 2024 | 82.63 Bn |
| Dec 31, 2023 | 79.32 Bn |
| Jun 30, 2023 | 80.40 Bn |
| Dec 31, 2022 | 72.98 Bn |
| Jun 30, 2022 | 77.40 Bn |
| Dec 31, 2021 | 79.46 Bn |
| Jun 30, 2021 | 77.49 Bn |
| Dec 31, 2020 | 74.86 Bn |
| Jun 30, 2020 | 68.59 Bn |
| Dec 31, 2019 | 67.62 Bn |
| Jun 30, 2019 | 71.37 Bn |
| Dec 31, 2018 | 75.47 Bn |
| Sep 30, 2018 | 1.15 Bn |